With the recovery of industry prosperity and favorable policies, over 50 biomedicine A-share companies are expected to report profits in 2025

Benefiting from the gradually improving industry prosperity, continuous expansion into overseas markets, and the implementation of favorable policies for the pharmaceutical sector, A-share biopharmaceutical companies are continuously delivering innovative results in resilient development in 2025. According to Wind data, as of January 26 at 18:00, more than 90 A-share biopharmaceutical companies have released performance forecasts for 2025, with 53 companies expected to achieve profitability. From the lower limit of the forecasted net profit growth, 14 companies expect to double their net profit (excluding those turning losses into profits or reducing losses). In addition, companies such as Yiling Pharmaceutical and Chutian Technology are expected to turn losses into profits, while companies like Dize Pharmaceutical and Mengke Pharmaceutical are expected to reduce losses year-on-year. (Shanghai Securities Journal)